DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: Comparison of PAX6 and SOX1 expression during neural induction

M. Diana Neely, Michael J. Litt, Andrew M. Tidball, Gary G. Li, Asad A. Aboud, Corey R. Hopkins, Reed Chamberlin, Charles C. Hong, Kevin C. Ess, Aaron B. Bowman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Recent successes in deriving human-induced pluripotent stem cells (hiPSCs) allow for the possibility of studying human neurons derived from patients with neurological diseases. Concomitant inhibition of the BMP and TGF-β1 branches of the TGF-β signaling pathways by the endogenous antagonist, Noggin, and the small molecule SB431542, respectively, induces efficient neuralization of hiPSCs, a method known as dual-SMAD inhibition. The use of small molecule inhibitors instead of their endogenous counterparts has several advantages including lower cost, consistent activity, and the maintenance of xeno-free culture conditions. We tested the efficacy of DMH1, a highly selective small molecule BMP-inhibitor for its potential to replace Noggin in the neuralization of hiPSCs. We compare Noggin and DMH1-induced neuralization of hiPSCs by measuring protein and mRNA levels of pluripotency and neural precursor markers over a period of seven days. The regulation of five of the six markers assessed was indistinguishable in the presence of concentrations of Noggin or DMH1 that have been shown to effectively inhibit BMP signaling in other systems. We observed that by varying the DMH1 or Noggin concentration, we could selectively modulate the number of SOX1 expressing cells, whereas PAX6, another neural precursor marker, remained the same. The level and timing of SOX1 expression have been shown to affect neural induction as well as neural lineage. Our observations, therefore, suggest that BMP-inhibitor concentrations need to be carefully monitored to ensure appropriate expression levels of all transcription factors necessary for the induction of a particular neuronal lineage. We further demonstrate that DMH1-induced neural progenitors can be differentiated into β3-tubulin expressing neurons, a subset of which also express tyrosine hydroxylase. Thus, the combined use of DMH1, a highly specific BMP-pathway inhibitor, and SB431542, a TGF-β1-pathway specific inhibitor, provides us with the tools to independently regulate these two pathways through the exclusive use of small molecule inhibitors. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)482-491
Number of pages10
JournalACS Chemical Neuroscience
Volume3
Issue number6
DOIs
StatePublished - Jun 20 2012

Fingerprint

Induced Pluripotent Stem Cells
Neurogenesis
Stem cells
Molecules
Neurons
Tyrosine 3-Monooxygenase
Tubulin
Transcription Factors
Maintenance
Costs and Cost Analysis
Messenger RNA
Costs
Proteins
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide

Keywords

  • Induced pluripotent stem cells
  • TGF-β
  • iPS
  • neural differentiation
  • neural induction
  • transcription factors

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs : Comparison of PAX6 and SOX1 expression during neural induction. / Neely, M. Diana; Litt, Michael J.; Tidball, Andrew M.; Li, Gary G.; Aboud, Asad A.; Hopkins, Corey R.; Chamberlin, Reed; Hong, Charles C.; Ess, Kevin C.; Bowman, Aaron B.

In: ACS Chemical Neuroscience, Vol. 3, No. 6, 20.06.2012, p. 482-491.

Research output: Contribution to journalArticle

Neely, M. Diana ; Litt, Michael J. ; Tidball, Andrew M. ; Li, Gary G. ; Aboud, Asad A. ; Hopkins, Corey R. ; Chamberlin, Reed ; Hong, Charles C. ; Ess, Kevin C. ; Bowman, Aaron B. / DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs : Comparison of PAX6 and SOX1 expression during neural induction. In: ACS Chemical Neuroscience. 2012 ; Vol. 3, No. 6. pp. 482-491.
@article{1a1788bd557a45f7af33800d64eee5fb,
title = "DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: Comparison of PAX6 and SOX1 expression during neural induction",
abstract = "Recent successes in deriving human-induced pluripotent stem cells (hiPSCs) allow for the possibility of studying human neurons derived from patients with neurological diseases. Concomitant inhibition of the BMP and TGF-β1 branches of the TGF-β signaling pathways by the endogenous antagonist, Noggin, and the small molecule SB431542, respectively, induces efficient neuralization of hiPSCs, a method known as dual-SMAD inhibition. The use of small molecule inhibitors instead of their endogenous counterparts has several advantages including lower cost, consistent activity, and the maintenance of xeno-free culture conditions. We tested the efficacy of DMH1, a highly selective small molecule BMP-inhibitor for its potential to replace Noggin in the neuralization of hiPSCs. We compare Noggin and DMH1-induced neuralization of hiPSCs by measuring protein and mRNA levels of pluripotency and neural precursor markers over a period of seven days. The regulation of five of the six markers assessed was indistinguishable in the presence of concentrations of Noggin or DMH1 that have been shown to effectively inhibit BMP signaling in other systems. We observed that by varying the DMH1 or Noggin concentration, we could selectively modulate the number of SOX1 expressing cells, whereas PAX6, another neural precursor marker, remained the same. The level and timing of SOX1 expression have been shown to affect neural induction as well as neural lineage. Our observations, therefore, suggest that BMP-inhibitor concentrations need to be carefully monitored to ensure appropriate expression levels of all transcription factors necessary for the induction of a particular neuronal lineage. We further demonstrate that DMH1-induced neural progenitors can be differentiated into β3-tubulin expressing neurons, a subset of which also express tyrosine hydroxylase. Thus, the combined use of DMH1, a highly specific BMP-pathway inhibitor, and SB431542, a TGF-β1-pathway specific inhibitor, provides us with the tools to independently regulate these two pathways through the exclusive use of small molecule inhibitors. (Figure Presented).",
keywords = "Induced pluripotent stem cells, TGF-β, iPS, neural differentiation, neural induction, transcription factors",
author = "Neely, {M. Diana} and Litt, {Michael J.} and Tidball, {Andrew M.} and Li, {Gary G.} and Aboud, {Asad A.} and Hopkins, {Corey R.} and Reed Chamberlin and Hong, {Charles C.} and Ess, {Kevin C.} and Bowman, {Aaron B.}",
year = "2012",
month = "6",
day = "20",
doi = "10.1021/cn300029t",
language = "English (US)",
volume = "3",
pages = "482--491",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs

T2 - Comparison of PAX6 and SOX1 expression during neural induction

AU - Neely, M. Diana

AU - Litt, Michael J.

AU - Tidball, Andrew M.

AU - Li, Gary G.

AU - Aboud, Asad A.

AU - Hopkins, Corey R.

AU - Chamberlin, Reed

AU - Hong, Charles C.

AU - Ess, Kevin C.

AU - Bowman, Aaron B.

PY - 2012/6/20

Y1 - 2012/6/20

N2 - Recent successes in deriving human-induced pluripotent stem cells (hiPSCs) allow for the possibility of studying human neurons derived from patients with neurological diseases. Concomitant inhibition of the BMP and TGF-β1 branches of the TGF-β signaling pathways by the endogenous antagonist, Noggin, and the small molecule SB431542, respectively, induces efficient neuralization of hiPSCs, a method known as dual-SMAD inhibition. The use of small molecule inhibitors instead of their endogenous counterparts has several advantages including lower cost, consistent activity, and the maintenance of xeno-free culture conditions. We tested the efficacy of DMH1, a highly selective small molecule BMP-inhibitor for its potential to replace Noggin in the neuralization of hiPSCs. We compare Noggin and DMH1-induced neuralization of hiPSCs by measuring protein and mRNA levels of pluripotency and neural precursor markers over a period of seven days. The regulation of five of the six markers assessed was indistinguishable in the presence of concentrations of Noggin or DMH1 that have been shown to effectively inhibit BMP signaling in other systems. We observed that by varying the DMH1 or Noggin concentration, we could selectively modulate the number of SOX1 expressing cells, whereas PAX6, another neural precursor marker, remained the same. The level and timing of SOX1 expression have been shown to affect neural induction as well as neural lineage. Our observations, therefore, suggest that BMP-inhibitor concentrations need to be carefully monitored to ensure appropriate expression levels of all transcription factors necessary for the induction of a particular neuronal lineage. We further demonstrate that DMH1-induced neural progenitors can be differentiated into β3-tubulin expressing neurons, a subset of which also express tyrosine hydroxylase. Thus, the combined use of DMH1, a highly specific BMP-pathway inhibitor, and SB431542, a TGF-β1-pathway specific inhibitor, provides us with the tools to independently regulate these two pathways through the exclusive use of small molecule inhibitors. (Figure Presented).

AB - Recent successes in deriving human-induced pluripotent stem cells (hiPSCs) allow for the possibility of studying human neurons derived from patients with neurological diseases. Concomitant inhibition of the BMP and TGF-β1 branches of the TGF-β signaling pathways by the endogenous antagonist, Noggin, and the small molecule SB431542, respectively, induces efficient neuralization of hiPSCs, a method known as dual-SMAD inhibition. The use of small molecule inhibitors instead of their endogenous counterparts has several advantages including lower cost, consistent activity, and the maintenance of xeno-free culture conditions. We tested the efficacy of DMH1, a highly selective small molecule BMP-inhibitor for its potential to replace Noggin in the neuralization of hiPSCs. We compare Noggin and DMH1-induced neuralization of hiPSCs by measuring protein and mRNA levels of pluripotency and neural precursor markers over a period of seven days. The regulation of five of the six markers assessed was indistinguishable in the presence of concentrations of Noggin or DMH1 that have been shown to effectively inhibit BMP signaling in other systems. We observed that by varying the DMH1 or Noggin concentration, we could selectively modulate the number of SOX1 expressing cells, whereas PAX6, another neural precursor marker, remained the same. The level and timing of SOX1 expression have been shown to affect neural induction as well as neural lineage. Our observations, therefore, suggest that BMP-inhibitor concentrations need to be carefully monitored to ensure appropriate expression levels of all transcription factors necessary for the induction of a particular neuronal lineage. We further demonstrate that DMH1-induced neural progenitors can be differentiated into β3-tubulin expressing neurons, a subset of which also express tyrosine hydroxylase. Thus, the combined use of DMH1, a highly specific BMP-pathway inhibitor, and SB431542, a TGF-β1-pathway specific inhibitor, provides us with the tools to independently regulate these two pathways through the exclusive use of small molecule inhibitors. (Figure Presented).

KW - Induced pluripotent stem cells

KW - TGF-β

KW - iPS

KW - neural differentiation

KW - neural induction

KW - transcription factors

UR - http://www.scopus.com/inward/record.url?scp=84862836435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862836435&partnerID=8YFLogxK

U2 - 10.1021/cn300029t

DO - 10.1021/cn300029t

M3 - Article

C2 - 22860217

AN - SCOPUS:84862836435

VL - 3

SP - 482

EP - 491

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 6

ER -